Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COREVAX-1 DC vaccine after resection in stage IV colorectal cancer
2024-516221-31-00Phase 2Authorised
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
- Start
- Sep 2024
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of DC-VACCINE IRST-IRCCS in colorectal cancer (CRC), sponsored by Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori". Primary endpoints: Type, incidence, and severity of adverse events, Quantification of circulating immune effectors specific for tumor antigens and 1 more. Planned start Sep 2024; status: authorised.
02
Drugs
DC-VACCINE IRST-IRCCS
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2024-516221-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516221-31-00.